Literature DB >> 22151822

Factors associated with severity on admission and in-hospital mortality after primary intracerebral hemorrhage in China.

Xian Fu1, Ka Sing Wong, Jade W Wei, Xiangyan Chen, Yueqing Lin, JinSheng Zeng, Ruxun Huang, Qingchun Gao.   

Abstract

BACKGROUND AND
PURPOSE: Of the stroke types, intracerebral hemorrhage is the most debilitating and fatal. The aim of the current study was to determine factors that influence the severity and in-hospital mortality after primary intracerebral hemorrhage.
METHODS: Data were collected retrospectively on 1268 patients with primary intracerebral hemorrhage admitted to stroke units at participating hospitals in Guangzhou between January 2005 and August 2008. Logistic regression analysis was used to determine factors associated with severity on admission and in-hospital mortality.
RESULTS: Of the 1268 patients, 20·4% were reported to have a severe stroke on admission, and the in-hospital mortality rate was 12·5%. Severity on admission was strongly associated with Glasgow Coma Scale score on admission (odds ratio = 0·89, 95% confidence interval 0·85-0·94) and hematoma location. Notably, basal ganglia hemorrhages were associated with increased severity (odds ratio = 1·40, 95% confidence interval 1·03-1·90), and cerebellar hemorrhages were associated with reduced severity (odds ratio = 0·29, 95% confidence interval 0·10-0·84). In-hospital mortality was not only correlated with Glasgow Coma Scale score on admission (odds ratio = 0·79, 95% confidence interval 0·74-0·84) and basal ganglia location (odds ratio = 0·47, 95% confidence interval 0·26-0·83), but also with dysnatremia (odds ratio = 1·91, 95% confidence interval 1·08-3·40) and comorbidities such as upper gastrointestinal hemorrhage (odds ratio = 2·28, 95% confidence interval 1·33-3·91), pneumonia (odds ratio = 3·50, 95% confidence interval 2·17-5·63), urinary incontinence (odds ratio = 2·22, 95% confidence interval 1·40-3·51), and renal dysfunction (odds ratio = 2·28, 95% confidence interval 1·42-3·65).
CONCLUSION: Glasgow Coma Scale score and hematoma locations were independently associated with severity on admission and in-hospital mortality after primary intracerebral hemorrhage. The study also highlights the deleterious effect of comorbidities on in-hospital mortality following primary intracerebral hemorrhage in China.
© 2011 The Authors. International Journal of Stroke © 2011 World Stroke Organization.

Entities:  

Mesh:

Year:  2011        PMID: 22151822     DOI: 10.1111/j.1747-4949.2011.00712.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  5 in total

Review 1.  Magnitude and Predictors of In-Hospital Stroke Mortality in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Amare Abera Tareke; Masrie Getnet Abate; Addis Alem; Yoseph Merkeb Alamneh; Alehegn Aderaw Alamneh; Yikeber Argachew Deml; Mulu Shiferaw; Woldeteklehaymanot Kassahun; Abraham Teym
Journal:  Stroke Res Treat       Date:  2022-05-24

2.  Intermittent versus continuous tube feeding in patients with hemorrhagic stroke: a randomized controlled clinical trial.

Authors:  Yan Jiang; Jiping Li; Wei Zhu
Journal:  Eur J Clin Nutr       Date:  2020-03-09       Impact factor: 4.016

3.  Medical acute complications of intracerebral hemorrhage in young adults.

Authors:  Riku-Jaakko Koivunen; Elena Haapaniemi; Jarno Satopää; Mika Niemelä; Turgut Tatlisumak; Jukka Putaala
Journal:  Stroke Res Treat       Date:  2015-02-02

4.  Analysis on geographic variations in hospital deaths and endovascular therapy in ischaemic stroke patients: an observational cross-sectional study in China.

Authors:  Hui Chen; Lizheng Shi; Ni Wang; Yangtong Han; Yilu Lin; Mingfeng Dai; Honglei Liu; Xiao Dong; Ming Xue; Hua Xu
Journal:  BMJ Open       Date:  2019-06-24       Impact factor: 2.692

5.  Determinants of quality of life in patients with hemorrhagic stroke: A path analysis.

Authors:  Wei Zhu; Yan Jiang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.